GLUT1, GLUT3 Expression and 18FDG-PET/CT in Human Malignant Melanoma: What Relationship Exists? New Insights and Perspectives.
GLUT1
GLUT3
immunohistochemistry
malignant melanoma
perspectives
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
09 11 2021
09 11 2021
Historique:
received:
14
10
2021
revised:
03
11
2021
accepted:
07
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
24
12
2021
Statut:
epublish
Résumé
Malignant melanoma is the most aggressive of skin cancers and the 19th most common cancer worldwide, with an estimated age-standardized incidence rate of 2.8-3.1 per 100,000; although there have been clear advances in therapeutic treatment, the prognosis of MM patients with Breslow thickness greater than 1 mm is still quite poor today. The study of how melanoma cells manage to survive and proliferate by consuming glucose has been partially addressed in the literature, but some rather interesting results are starting to be present. A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and a search of PubMed and Web of Sciences (WoS) databases was performed until 27 September 2021 using the terms: glucose transporter 1 and 3 and GLUT1/3 in combination with each of the following: melanoma, neoplasm and immunohistochemistry. In total, 46 records were initially identified in the literature search, of which six were duplicates. After screening for eligibility and inclusion criteria, 16 publications were ultimately included. the results discussed regarding the role and expression of GLUT are still far from definitive, but further steps toward understanding and stopping this mechanism have, at least in part, been taken. New studies and new discoveries should lead to further clarification of some aspects since the various mechanisms of glucose uptake by neoplastic cells are not limited to the transporters of the GLUT family alone.
Sections du résumé
BACKGROUND
Malignant melanoma is the most aggressive of skin cancers and the 19th most common cancer worldwide, with an estimated age-standardized incidence rate of 2.8-3.1 per 100,000; although there have been clear advances in therapeutic treatment, the prognosis of MM patients with Breslow thickness greater than 1 mm is still quite poor today. The study of how melanoma cells manage to survive and proliferate by consuming glucose has been partially addressed in the literature, but some rather interesting results are starting to be present.
METHODS
A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and a search of PubMed and Web of Sciences (WoS) databases was performed until 27 September 2021 using the terms: glucose transporter 1 and 3 and GLUT1/3 in combination with each of the following: melanoma, neoplasm and immunohistochemistry.
RESULTS
In total, 46 records were initially identified in the literature search, of which six were duplicates. After screening for eligibility and inclusion criteria, 16 publications were ultimately included.
CONCLUSIONS
the results discussed regarding the role and expression of GLUT are still far from definitive, but further steps toward understanding and stopping this mechanism have, at least in part, been taken. New studies and new discoveries should lead to further clarification of some aspects since the various mechanisms of glucose uptake by neoplastic cells are not limited to the transporters of the GLUT family alone.
Identifiants
pubmed: 34831313
pii: cells10113090
doi: 10.3390/cells10113090
pmc: PMC8624914
pii:
doi:
Substances chimiques
Glucose Transporter Type 1
0
Glucose Transporter Type 3
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Références
Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1774-82
pubmed: 19495748
Nucl Med Biol. 2012 Nov;39(8):1167-72
pubmed: 22901702
EJC Suppl. 2013 Sep;11(2):81-91
pubmed: 26217116
Am J Dermatopathol. 2014 May;36(5):363-79
pubmed: 24803061
Dermatopathology (Basel). 2021 Jul 05;8(3):271-276
pubmed: 34287308
J Biol Chem. 2018 Oct 12;293(41):15947-15961
pubmed: 30158244
Melanoma Res. 2019 Dec;29(6):603-611
pubmed: 31135601
Int J Cancer. 2011 May 1;128(9):2085-95
pubmed: 20607826
Ann Anat. 2010 May 20;192(3):133-8
pubmed: 20395120
Oncotarget. 2016 Oct 4;7(40):64778-64784
pubmed: 27556188
Cell Chem Biol. 2019 Sep 19;26(9):1214-1228.e25
pubmed: 31303578
J Dermatol. 2005 May;32(5):316-34
pubmed: 16043894
Theranostics. 2020 Jul 25;10(21):9579-9590
pubmed: 32863946
J Exp Clin Cancer Res. 2008 Sep 02;27:34
pubmed: 18764953
Cancer Biol Ther. 2019;20(11):1366-1379
pubmed: 31366280
J Clin Diagn Res. 2017 Jun;11(6):EC09-EC16
pubmed: 28764171
Urology. 2000 Mar;55(3):448-52
pubmed: 10699635
Int J Mol Sci. 2020 Dec 08;21(24):
pubmed: 33302435
PLoS One. 2019 Jun 17;14(6):e0217781
pubmed: 31206524
Cancer J. 2004 Jul-Aug;10(4):262-70
pubmed: 15383207
Arch Biochem Biophys. 2014 Dec 1;563:79-93
pubmed: 24997364
Oral Oncol. 2007 Sep;43(8):796-803
pubmed: 17207657
Pathol Oncol Res. 1998;4(2):115-20
pubmed: 9654596
Cancers (Basel). 2021 Sep 02;13(17):
pubmed: 34503234
Pathol Oncol Res. 2019 Jan;25(1):361-368
pubmed: 29128957
Mod Pathol. 1998 May;11(5):437-43
pubmed: 9619596
J Biol Chem. 1991 Dec 25;266(36):24632-6
pubmed: 1761560
J Natl Cancer Inst. 2002 Jul 17;94(14):1080-91
pubmed: 12122099
Oncotarget. 2017 Feb 21;8(8):13206-13213
pubmed: 28086215
Melanoma Res. 2002 Feb;12(1):35-43
pubmed: 11828256